Companies facing fewer funding sources, reimbursement issues
California’s biomedical industry is one of the largest in the world. In 2011, its more than 2,000 biomedical companies generated just under $70 billion in revenue, and the state represents about one-fifth of the total biomedical pipeline in the U.S, according to the California Biomedical Industry 2013 Report from California Healthcare Institute, BayBio and PwC. But despite its powerhouse status, the California biomedical industry still faces many challenges, according to the 175 biomedical CEOs who were surveyed for the report.
One such challenge is access to capital. Despite California being the No. 1 recipient nationwide of both venture capital and federal funding -- totaling $1.98 billion and $3.33 billion respectively in 2012 -- 74% of CEOs surveyed indicated that the reason R&D projects were delayed last year was because funding was not available. This figure is in stark contrast to 2011, when only 40% of CEOs indicated funding as an issue for delaying R&D.
Meanwhile, 59% of respondents cited limited or lack of access to capital as the most threatening issue to the short-term health of biomedical innovation.
Also stunting new projects last year were regulatory hurdles. Sixteen percent of respondents delayed a project because of regulation in 2012. But FDA seems to be less of a problem for pharma companies, as that number represents a 17% decline from the previous year, and nearly 14% of respondents said the FDA regulatory process had improved over the previous year.
As payers move toward pay-for-performance models, CEOs say reimbursement and health insurance issues will play a bigger role in preventing companies from successfully getting products to market. Three-quarters of CEOs surveyed said reimbursement became a bigger challenge for their company over the past year, up from 37 percent the previous year.
Read the complete report at www.californiabiomedreport.com.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.